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Abstract
In two harmonized efficacy studies to prevent HIV infection through multiple in-
fusions of the monoclonal antibody VRC01, a key objective is to evaluate whether
the serum concentration of VRC01, which changes cyclically over time along with the
infusion schedule, is associated with the rate of HIV infection. Simulation studies are
needed in the development of such survival models. In this paper, we consider simulat-
ing event time data with a continuous time-varying covariate whose values vary with
time through multiple drug administration cycles, and whose effect on survival changes
differently before and after a threshold within each cycle. The latter accommodates
settings with a zero-protection biomarker threshold above which the drug provides a
varying level of protection depending on the biomarker level, but below which the drug
provides no protection. We propose two simulation approaches: one based on simu-
lating survival data under a single-dose regimen first before data are aggregated over
multiple doses, and another based on simulating survival data directly under a multiple-
dose regimen. We generate time-to-event data following a Cox proportional hazards
model based on inverting the cumulative hazard function and a log link function for
relating the hazard function to the covariates. The method’s validity is assessed in
two sets of simulation experiments. The results indicate that the proposed procedures
perform well in producing data that conform to their cyclic nature and assumptions of
the Cox proportional hazards model.
keywords: correlates of risk analysis; exponential distribution; Monte Carlo methods;
survival data simulations; time-dependent covariate; zero-protection threshold.
1 Introduction
Time-to-event outcomes with time-varying covariates are frequently encountered in
biomedical studies. In the Phase 2b HIV-1 Antibody Mediated Prevention (AMP)
efficacy study to prevent HIV-1 infection through ten 8-weekly intravenous infusions
of a monoclonal antibody VRC01 [1], participants’ drug concentrations in serum are
expected to change continuously and cyclically over time, peaking within hours after
each infusion, declining at a faster rate in the first few days followed by a decay at a
slower rate, and possibly diminishing to an undetectable level through each infusion
cycle [2–4]. Population pharmacokinetics (popPK) analysis based on non-linear mixed
effects models is a commonly used tool to estimate population- and individual-level
PK parameters that characterize the drug decay process, as well as to estimate drug
concentrations over time overall and for each individual. The primary objective of
AMP is to evaluate the prevention efficacy of VRC01 (vs. placebo) at dose levels of 10
mg/Kg and 30 mg/Kg. A key secondary objective is to assess the association of VRC01
serum concentration (or other functional biomarkers) over time with the instantaneous
rate of HIV infection in the AMP correlates of risk (CoR) analyses [1].
Simulation studies are often needed in the development of such CoR models with
time-to-event outcome and time-varying covariates. An essential starting point is to
produce simulated survival times from a known data generating process [5–8]. For
continuous covariates, previous work has been limited to simulating event times with
time-varying covariates that follow a simple linear relationship with time and/or log-
transformed time [9–11], or covariates that change at integer-valued steps of the time
scale [12] throughout the entire follow up period. Such data generating processes
are only appropriate when individuals are uniformly exposed to risk of acquiring the
survival outcome at each unit of time (e.g., oral daily dose of the same drug amount).
Therefore, new or extensions of these methods are needed for settings like the AMP
study, where continuous covariate values change over time in a cyclic non-monotone
form.
Cox proportional hazards (PH) regression models are the most common approach
for evaluating the effect of covariates, including time-varying covariates on survival
outcomes. The objective of this paper is to develop a method for the generation of
survival times that follow a Cox PH model with cyclic time-varying covariates. We
consider a continuous time-varying covariate whose value varies with time periodically
through cycles of multiple drug administrations. In addition, within each cycle, the
covariate’s effect on survival may differ before and after a threshold value is reached.
For example, under a zero-protection threshold model, when above a certain threshold
value, the covariate’s effect on the survival outcome follows a certain function. However,
when below the threshold value, the covariate has no effect on survival. We generate
time-to-event data following a Cox PH model based on inverting the cumulative hazard
function and a log link function for relating the hazard function to the time-varying
and time-invariant covariates. We consider closed-form derivations for simulating three
commonly used distributions: Exponential, Weibull and Gompertz, all of which satisfy
the PH assumptions. We propose two simulation approaches. The first approach is
based on simulating survival data under a single-dose regimen before such data are
aggregated over multiple-dose intervals; the second approach is based on simulating
survival data directly under a multiple-dose regimen.
The paper is structured as follows. In Section 2, we briefly review previous work
on generating survival times via Cox models. We introduce both the single-dose and
multiple-dose approaches for simulating survival time with continuous and cyclic time-
varying covariates. For the single-dose approach, we provide, under the zero-protection
model, details of the closed-form derivations of event times following an Exponential
distribution in the main text; derivations for Weibull- and Gompertz-distributed event
times are presented in the Appendix. For the multiple-dose approach, we provide
details of the derivations assuming a monotonic relationship between the time-varying
covariate and the survival outcome within each dosing cycle in the main text; extensions
incorporating the zero-protection model are provided in the Appendix. In Section 3, we
describe two simulation experiments to assess the developed method with application
to the AMP CoR study. Conclusions are provided in Section 4.
2 Simulating survival times
2.1 Review
We first briefly describe basic steps of simulating survival times based on Cox PH
model as discussed in [5–12]. The Cox PH model is given by
h(t|x, z(t)) = h0(t)exp(βz(t) + η′x), (1)
where z(t) denotes the time-varying covariate, whose value changes over the duration
of the follow-up time, while its effect on the hazard of the outcome stays constant as
denoted by the regression coefficient β; x denotes the time-invariant covariates, and η
is the vector of regression coefficients associated with the vector of fixed covariates x.
h0(t) is the baseline hazard function, i.e., the hazard function of the outcome for those
subjects with x = 0 and z(t) = 0.
As the Cox model is formulated through the hazard function, the simulation of
appropriate survival times for this model needs further manipulation based on the rela-
tionship between the hazard function and the covariate. A small number of prior studies
have developed methods for simulating event time data with time-varying covariates.
Leemis et al. [6] briefly described methods based on inverting the cumulative hazard
function to generate event times in settings with time-varying covariates, Sylvestre and
Abrahamowicz [13] described a permutational algorithm and a binomial model for sim-
ulating event times conditional of time-varying covariates, and Austin [9,10] extended
the work of Leemis et al. [5,6] using the log link function for relating the hazard func-
tion to the linear covariates and incorporated both time-invariant and time-varying
covariates.
The translation of the regression coefficients from hazard to survival time is rel-
atively easy if the baseline hazard function is constant, i.e. the survival times are
exponentially distributed and h0(t) = λ, λ > 0. The cumulative hazard function of
model (1) is given by:
H(t|x, z(t)) =
∫ t
0
λ exp(βz(u) + η′x) du. (2)
Because the survival function of the above model, S(t|x, z(t)) = exp(−H(t|x, z(t))) fol-
lows the standard uniform distribution U(0,1), both Leemis and Bender et al. [5–7] have
demonstrated that a survival time, T , can be generated by inverting the cumulative
hazard function via T = H−1(−log(u)), where u ∼ U(0, 1).
2.2 Proposed methods
For concreteness, we describe our methods in the context of the AMP study. The
same data generating process can be generalized to other applicable biomedical set-
tings, where the association between a time-to-event outcome and a cyclic time-varying
covariates is of interest. We define event time, t, as time (in days) from study enroll-
ment to HIV-1 infection, and the hazard of HIV-1 infection is modeled as a function of
time-varying drug concentration over time according to Equation (1) in a Cox model.
Suppose a maximal number of m infusions are planned for each individual. Let I1, I2,
..., Im−1 indicate the m− 1 infusion interval lengths between the m infusions, and Im
indicate the interval between the last infusion and the end of the study. Note that m
takes values between 1 and 10 in AMP, and m could differ between individuals due to
missed infusions under imperfect infusion adherence. Under a zero-protection thresh-
old model, the time-varying covariate within a given infusion interval Ik, k = 1, . . . ,m,
is defined as follows:
z(t) =

t if t ≤ ts,
ts otherwise,
(3)
where ts indicates the time (since infusion) when drug concentration reaches a zero-
protection threshold s. In other words, for t ≤ ts, we consider z(t) as a proxy of
drug concentrations at time t because drug concentrations are expected to change with
time in a monotonic relationship, and consequently, as shown in Equation (1) the
instantaneous hazard h(t) changes at a rate of exp(β) per-day change in t. For t > ts,
zt remains constant so that h(t) does not continue to change until the next infusion
takes place. In many biomedical settings, ts is considered as the time-point when a
therapeutic or protection threshold is achieved. In addition, time-invariant covariates,
x, could be a vector of individual-level random-effects PK parameters used to describe
the inter-individual variability of the PK processes based on non-linear mixed effects
modeling of the time-concentration data in a study cohort [4]. An example of x is the
estimated individual-level clearance rate of VRC01. We extend the work of Austin [9]
and consider both time-invariant covariates x and a continuous time-varying covariate
z(t), whose values change over time in a cyclic form and whose effects on survival
change in a piece-wise manner within each cycle.
Besides the PH assumption, both the single-dose and multiple-dose approaches
described below rely on the ‘cycle-invariant’ assumption that the effect of the cyclic
time-varying covariate on survival does not change between cycles. This assumption
is reasonable in the context of AMP for two reasons. First, pharmacologically steady
state is expected to be reached after 5–6 half-lives of a drug. This implies that the
time-concentration curve of VRC01 fluctuates in the same pattern over subsequent
dosing intervals after the second dose at 8 weeks, because the half life of VRC01 is
approximately two weeks. Second, VRC01 exhibits a linear or dose-independent PK
feature in that the PK parameters used to describe its time-concentration curve do not
change when different doses or multiple doses of VRC01 are given [4].
2.2.1 Single-dose approach
The single-dose approach considers simulating survival data over one dose interval as
a first step before such data are aggregated over multiple dose intervals. Instead of
having the same continuous relationship with t throughout the entire follow up time as
described in [10], z(t) in our case changes at ts within each drug administration cycle, as
shown in Equation (3). This feature guards against the possibility of the hazard in the
treatment group becoming greater than that in the control group when t gets too large
due to a missed infusion. In addition, we assume that the instantaneous hazard at ts as
h(t = ts|x, z(t)) = λ exp(βts + η′x) = λp, or equivalently, λ exp(η′x) = λp exp(−βts) ,
where λp indicates the hazard rate in the control group where no effect of the drug on
survival is expected to be observed.
In reality, ts could differ across individuals who receive different weight-based dose
amounts due to different body weights, or who have different values of other covari-
ates that may influence the inter-individual variability of various PK parameters for
VRC01. For simplicity and faster computation, an average ts can be used in the actual
simulation of survival times. For example, based on the popPK model of VRC01 de-
scribed in [4], we estimate that it takes an average of 57 or 81 days, respectively, for the
drug concentration of a potential AMP participant with body weight of 74.5 Kg receiv-
ing the 10mg/Kg or 30 mg/Kg dose VRC01 to decline to s = 5.0 mcg/mL, a VRC01
concentration that is hypothesized to confer protection against HIV infection [14–17].
This implies that ts = 57 days for the 10 mg/Kg dose group, and ts = 81 days for
the 30 mg/Kg dose group. The instantaneous hazard remains constant after 57 and 81
days, respectively, in the low and high dose groups. This ensures meaningful simulated
survival time to account for the wide infusion visit window in AMP (-1 week to +7
weeks around the target 8-weekly infusion visits) and for individuals whose infusion
intervals are great than 8 weeks due to missed infusions.
Now, we describe first the steps to simulate survival times after a single dose,
by inverting the cumulative hazard function. In the following, we show derivations
in details for Exponential distribution of survival times; details for the Weibull and
Gompertz distributions are reported in Appendix A1 and A2, respectively.
For exponentially-distributed survival times, h0(t) = λ. If t ≤ ts, the cumulative
hazard function is equal to
H(t, x, z(t)) =
∫ t
0
λ exp(βz(u) + η′x) du
=
∫ t
0
λ exp(βu+ η′x) du
= λ exp(η′x)
∫ t
0
exp(βu) du
= λ exp(η′x)
[
1
β
exp(βu)
]t
0
=
λ exp(η′x)
β
[ exp(βt)− 1] .
Consequently, the inverse cumulative hazard function is
H−1(v) =
1
β
log
(
1 +
βv
λ exp(η′x)
)
.
Therefore, an event time can be generated as
T =
1
β
log
(
1 +
β(− log(u))
λ exp(η′x)
)
, if− log(u) < λ exp(η
′x)
β
[ exp(βts)− 1] , (4)
where u ∼ U(0, 1).
If t > ts, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ ts
0
λ (βu+ η′x) du+
∫ t
ts
λ exp(βts + η
′x), du
= λ exp(η′x)
(
1
β
(exp(βts)− 1) + (t− ts) exp(βts)
)
.
Consequently, the inverse cumulative hazard function is
H−1(v) =
v
λ exp(βts + η′x)
+
1− exp(βts)
β exp(βts)
+ ts.
Therefore, an event time can be generated as
T =
−log(u)
λ exp(βts + η′x)
+
1− exp(βts)
β exp(βts)
+ts, if −log(u) ≥ λ exp(η
′x)
β
[ exp(βts)− 1] ,
(5)
where u ∼ U(0, 1).
In summary, in order to simulate survival times under a zero-protection threshold
model after a single dose is given, a random uniform sample, u is first simulated and
the survival time takes the form in Equation (4) if −log(u) < λ exp(η′x)β [ exp(βts)− 1],
or the form in Equation (5), otherwise.
After the single-dose survival time according to the Exponential, Weibull, or Gom-
pertz distribution is simulated as described above or in the Appendix, the survival time
after multiple doses can be simulated as follows:
1. Simulate the infusion times for each individual’s m infusions. Infusion visit win-
dows and possible missed infusions and/or permanent infusion discontinuations
could be considered here;
2. For each individual, independently simulate the single-dose survival time T1, T2,
..., Tm for each of the m infusion intervals according to equations [4] and [5];
3. If all Tk > Ik, k = 1, 2, . . . , m, then the final multiple-dose survival time of
this uninfected individual is censored at S =
m∑
i=1
Ii. Otherwise, pick the first k
that satisfies Tk < Ik, and the final multiple-dose survival time for this infected
individual is S =
k−1∑
i=1
Ii + Tk.
This approach guarantees that, as desired, the event time follows the same survival
function within each infusion interval, and the probability of infection during a given
interval is not affected by the probability of the same individual not being infected in
the prior infusion interval because P(infected in t2) = P(infected in t2 | not infected in
t1) = P (T2 < t2 | T1 > t1) = P (T2 < t2) (given the all Tk’s are i.i.d).
2.2.2 Multiple-dose approach
The multiple-dose approach considers simulating survival data over multiple dose inter-
vals directly. In the multiple-dose setting, let (t1, ..., tm) denote the actual infusion time
(since enrollment) for the first to last mth infusion one receives, where m ≤ 10 accord-
ing to the AMP protocol. The first infusion coincides with enrollment and hence t1 = 0.
Using the notations from the single-dose approach, ti+1 = ti + Ii, for i = 1, 2, ...,m-1.
If ts is always greater than all dosing intervals, e.g., under perfect adherence to the
8-weekly infusion schedule, the following steps can be used to generate survival times
for participants receiving up to m doses. If ts may be smaller than a dosing interval,
then similar strategies as illustrated in Section 2.1.1 by combining the cumulative
hazards before ts and after ts can be employed for simulating survival times via the
multiple-dose approach (Appendix: A3). Similarly, survival times can be simulated by
inverting the cumulative hazard function. In the following derivations, survival times
are assumed to be exponentially-distributed.
If t1 ≤ t < t2, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ t
0
λ exp(βz(u) + η′x) du
=
∫ t
0
λ exp(βu+ η′x) du
= λ exp(η′x)
∫ t
0
exp(βu) du
= λ exp(η′x)
[
1
β
exp(βu)
]t
0
=
λ
β
exp(η′x) [ exp(βt)− 1] .
Consequently, the inverse cumulative hazard function is
H−1(u) =
1
β
log
(
1 +
βu
λ exp(η′x)
)
.
Therefore, an event time can be generated as
T =
1
β
log
(
1 +
β(− log(u))
λ exp(η′x)
)
, if− log(u) < b1 (6)
where b1 =
λ
β exp(η
′x) [ exp(βt2)− 1] , and u ∼ U(0, 1).
If t2 ≤ t < t3, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ t
0
λ exp(βz(u) + η′x) du
= λ exp(η′x)
∫ t
0
exp(βu) du
= λ exp(η′x)
(∫ t2
0
exp(βu) du+
∫ t
t2
exp(β(u− t2)) du
)
= λ exp(η′x)
(
1
β
(exp(βt2)− 1) + 1
β
(exp(βt− βt2)− 1)
)
=
λ
β
exp(η′x) (exp(βt2) + exp(βt− βt2)− 2) .
Consequently, the inverse cumulative hazard function is
H−1(u) =
1
β
log
(
exp(βt2)
(
βu
λ exp(η′x)
− exp(βt2) + 2
))
.
Therefore, an event time can be generated as
T =
1
β
log
(
exp(βt2)
(
β(−log(u))
λ exp(η′x)
− exp(βt2) + 2
))
, if a2 ≤ −log(u) < b2,
where
a2 =
λ
β
exp(η′x) ( exp(βt2)− 1) ,
b2 =
λ
β
exp(η′x) (exp(βt2) + exp(βt3 − βt2)− 2) , and
u ∼ U(0, 1).
Similarly, for tk ≤ t < tk+1, k = 2, . . . ,m − 1, the cumulative hazard function is
equal to
H(t, x, z(t)) =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) + exp(βt− βtk)− k
]
.
And the inverse cumulative hazard function is
H−1(u) =
1
β
log
(
exp(βtk)
(
βu
λexp(η′x)
−
k∑
i=2
exp(β(ti − ti−1)) + k
))
.
Therefore, an event time can be generated as
T =
1
β
log
(
exp(βtk)
(
β(−log(u))
λexp(η′x)
−
k∑
i=2
exp(β(ti − ti−1)) + k
))
, if ak ≤ −log(u) < bk,
(7)
where,
ak =
λ
β
exp(η′x)
(
k∑
i=2
exp(β(ti − ti−1))− (k − 1)
)
,
bk =
λ
β
exp(η′x)
(
k∑
i=2
exp(β(ti − ti−1) + exp(βtk+1 − βtk)− k
)
, and
u ∼ U(0, 1).
Lastly, if t ≥ tm, an event time can be generated as
T =
1
β
log
(
exp(βtm)
(
β(−log(u))
λ exp(η′x)
−
m∑
i=2
exp(β(ti − ti−1) +m
))
, if − log(u) ≥ bm,
(8)
where bm =
λ
β exp(η
′x)
(
m∑
i=2
exp(β(ti − ti−1)− (m− 1))
)
and u ∼ U(0, 1).
In summary, in order to simulate survival times in a multiple-dose setting, the
infusion times (t1, ..., tm) according to the study set-up and a random uniform sample,
u are first simulated. Then, for each k = 1, . . . ,m− 1, ak and bk are calculated where
a1=0 and ak+1 = bk. The survival time takes the form in Equation (6) if −log(u) < b1,
or the form in Equation (7) if ak ≤ −log(u) < bk, or the form in Equation (8) if
−log(u) ≥ b9.
3 Examples
We next illustrate the validity of the described survival data generating processes in
two simulation experiments. In the first experiment, the single-dose approach is used
to simulate survival data for 1000 AMP-like trials, each with n = 1500 participants in
each of the 10 mg/Kg VRC01, 30 mg/Kg VRC01 and placebo groups. Within each
trial, the time-varying covariate (i.e., drug concentration over time) is associated with
the survival outcome (i.e., time to HIV infection in days) according to Equation (1)
with β = 0.03 and η = 0 for both dose groups, and h0(t) = 0.04/365/exp(βts), where
ts = 57 and ts = 81 for the low and high dose groups, respectively to ensure the same
baseline HIV infection rate beyond ts in the two dose groups. In addition, z(t) takes
the piece-wise form as described in Equation (3) with a zero-protection threshold s = 5
mcg/mL. These parameter values indicate that, before an individual’s drug concentra-
tion reaches 5 mcg/mL, the hazard ratio over a 28-day period is exp(28 ∗ 0.03) = 2.31,
but the rate of infection remains constant (= 0.04/year) once the individual’s drug
concentration falls below 5 mcg/mL. We consider two study adherence levels: the high
and medium adherence scenarios assume 2% and 10% of infusion visits missed, re-
spectively. Consequently, we expect three patterns in the simulated data. First, the
low dose group should have higher risk of infection than the high dose group. This
is because drug concentrations in the former group on average are expected to reach
the zero-protection threshold, 5 mcg/mL in a shorter time or, in another word, the
lower dose group is expected to have a smaller ts=5mcg/mL than the higher dose group,
although the two dose groups do have the same risk (due to having the same β = 0.03)
until their respective ts=5mcg/mL time-points within each dosing cycle. Second, a lower
risk of infection should be associated with a better study adherence due to less missed
infusions and less follow up time with concentration below the zero-protection thresh-
old s = 5 mcg/mL. Third, a shorter duration between time of infection and prior
infusion should occur with better study adherence due to shorter average infusion in-
tervals when there are less missed infusions, although a smaller number of infections
do occur with a better study adherence. As shown in Figure 1, all these patterns are
confirmed. In addition, the mean (standard deviation) values of the estimated β from
fitting the simulated data in a standard Cox model with z(t) = time since prior infu-
sion as the time-varying covariate and ts ≥ study duration are 0.021(0.007) and 0.025
(0.01), respectively, for the low and high dose groups under high adherence. Under
medium adherence, these values are 0.013 (0.004) and 0.018 (0.006), respectively, for
the low and high dose groups. We note that under each adherence scenario, both βˆ
values are smaller than the true value of β = 0.03 because by setting ts greater, the
unit-effect of z(t) is expected to be smaller to achieve the same cumulative effect of
z(t) on h(t). We also note that under both adherence scenarios, βˆ is greater in the
high dose group than in the low dose group because in the simulated datasets the high
dose group subjects are more protected due to a longer time for their concentration to
drop to s and hence a larger unit-effect of z(t) is needed. Lastly, as expected, βˆ values
get closer to 0.03 as adherence improves.
In the second experiment, the multiple-dose approach is used to simulate AMP-like
trials under perfect study adherence scenarios with η = 0 and h0(t) = 0.04/365/exp(β∗
56). Each trial includes n = 1500 VRC01 recipients in each of the 10 mg/Kg and 30
mg/Kg dose groups. The same β value is used for both dose groups, but two different
β values: 0.01 and 0.03 are considered in order to verify how risk of infection varies by
β. Figure 2 shows that the probability of HIV infection within each 8-weekly infusion
cycle is smaller as β gets larger. This pattern is also expected because a higher β
indicates a larger effect of the biomarker in reducing the risk of infection. In addition,
as desired, the rate of HIV infection increases over time (as concentration gets lower)
within each infusion cycle, and the pattern remains the same over all cycles under the
‘cycle-invariant’ assumption described in Section 2.2.
4 Conclusions
In this paper, we considered simulating event time data with a continuous time-varying
covariate whose values vary with time through multiple repetitive cycles, and whose ef-
fect on survival changes differently before and after a threshold within each cycle. The
latter particularly accommodates settings with a zero-protection biomarker threshold
above which the drug provides a varying level of protection depending on the biomarker
level, but below which the drug provides no protection. We proposed two simulation
approaches: one based on simulating survival data under a single-dose regimen first be-
fore data are aggregated over multiple doses, and another based on simulating survival
data directly under a multiple-dose regimen. The derivations of the former are more
straightforward for handling different event time distributions and can be more easily
extended to data models with multiple protection threshold values within a cycle. The
derivations of the latter are more compact and simulations based on the latter approach
are generally faster than those based on the former approach. The latter approach is
also more flexible to be extended to data model where different z(t) functions may be
needed for different drug administration cycles.
The validity of our proposed methods were assessed in two sets of simulation exper-
iments. The results indicate that the proposed procedures perform well in producing
data that conform to their cyclic nature and the assumptions of the Cox PH model. Ex-
tension can be considered to add the number of doses as another time-dependent covari-
ate. Consequently, the ‘cycle-invariant’ assumption about the effect of the time-varying
covariates not changing between cycles can hence be relaxed. Lastly, for drugs that
do not satisfy the ‘cycle-invariant’ assumption, different β coefficients can be assumed
for each cycle and derivations of the simulation procedure based on the multiple-dose
approach can be similarly extended for such data models.
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Figure 1: Distributions of simulated event times since prior infusion
(Panel A) and since the first infusion (Panel B) under imperfect study
adherences. In these simulations, an annual HIV incidence rate of 4% is assumed for
the placebo group and β = 0.03 or HR= 2.32 per-28 days for both dose groups with
the zero-protection concentration threshold s = 5 mcg/mL in simulated trials of 4500
participants with a 1:1:1 ratio for the three treatment groups.
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Figure 2: Probability of HIV infection within each infusion interval fol-
lowing ten 8-weekly IV infusions of VRC01 under perfect study adherence
in a simulated trial of 3000 VRC01 recipients. Red lines are for β = 0.01 or
HR = 1.32 per-28 days; blue lines are for β = 0.03 or HR= 2.32 per-28 days.
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Appendix
A1: single-dose approach assuming Weibull distribution of survival times
The log of the Weibull hazard function is linear in log(t) and the hazard function can
be written as h0(t) = λγt
γ−1. Hence, the cumulative hazard function becomes
H(t|x, z(t)) =
∫ t
0
λγuγ−1 exp(βz(u) + η′x) du.
If t ≤ ts, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ t
0
λγuγ−1 exp(βz(u) + η′x) du
=
∫ t
0
λγuγ−1 exp(βu+ η′x) du
= λγ exp(η′x)
∫ t
0
uγ−1 exp(βu) du
= λγexp(η′x)
[
(−β)−γΓ (γ,−βu)]t
0
=
λγ exp(η′x)
(−β)γ [Γ (γ,−βt)− Γ (γ, 0)]
Consequently, the inverse cumulative hazard function is
H−1(v) = − 1
β
Γ−1
[
γ,
(−β)γv
λ exp(η′x)
+ Γ(γ, 0)
]
where Γ−1(γ, f(x)) represents the inverse upper incomplete gamma function. There-
fore, an event time can be generated as
T = − 1
β
Γ−1
[
γ,
(−β)γ(− log(u))
λ exp(η′x)
+ Γ(γ, 0)
]
, if
− log(u) < λγ exp(η
′x)
(−β)γ [Γ (γ,−βts)− Γ (γ, 0)] (9)
where u ∼ U(0, 1).
If t > ts, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ ts
0
λγuγ−1 exp(βu+ η′x)du+
∫ t
ts
λγtγ−1s exp(βts + η
′x)du
= λγ exp(η′x)
(
1
(−β)γ (Γ (γ,−βts)− Γ (γ, 0)) + (t− ts)t
γ−1
s exp(βts)
)
Consequently, the inverse cumulative hazard function is
H−1(v) =
v
tγ−1s λγ exp(βts + η′x)
− Γ (γ,−βts)− Γ (γ, 0)
tγ−1s (−β)γ exp(βts)
+ ts.
Therefore, an event time can be generated as
T =
− log(u)
tγ−1s λγ exp(βts + η′x)
− Γ (γ,−βts)− Γ (γ, 0)
tγ−1s (−β)γ exp(βts)
+ ts, if
− log(u) ≥ λγ exp(η
′x)
(−β)γ [Γ (γ,−βts)− Γ (γ, 0)] (10)
where u ∼ U(0, 1).
A2: single-dose approach assuming Gompertz distribution of survival times
The log of the Gompertz hazard function is linear in t and the hazard function can
be written as h0(t) = λ exp(αt). Hence, the cumulative hazard function becomes
H(t|x, z(t)) =
∫ t
0
λ exp(αu) exp(βz(u) + η′x) du.
If t ≤ ts, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ t
0
λ exp(αu) exp(βz(u) + η′x) du
=
∫ t
0
λ exp(αu) exp(βu+ η′x) du
= λ exp(η′x)
∫ t
0
exp((β + α)u) du
= λ exp(η′x)
[
1
β + α
exp((β + α)u)
]t
0
=
λ exp(η′x)
β + α
[ exp((β + α)t)− 1]
Consequently, the inverse cumulative hazard function is
H−1(v) =
1
β + α
log
(
1 +
(β + α)v
λ exp(η′x)
)
.
Therefore, an event time can be generated as
T =
1
β + α
log
(
1 +
(β + α)(− log(u))
λ exp(η′x)
)
, if
− log(u) < λ exp(η
′x)
β + α
[ exp((β + α)ts)− 1] (11)
where u ∼ U(0, 1).
If t > ts, the cumulative hazard function is equal to
H(t, x, z(t)) =
∫ ts
0
λ ((β + α)u+ η′x) du+
∫ t
ts
λ exp((β + α)ts + η
′x), du
= λ exp(η′x)
(
1
β + α
(exp((β + α)ts)− 1) + (t− ts) exp((β + α)ts)
)
Consequently, the inverse cumulative hazard function is
H−1(v) =
v
λ exp((β + α)ts + η′x)
+
1− exp((β + α)ts)
(β + α) exp((β + α)ts)
+ ts.
Therefore, an event time can be generated as
T =
−log(u)
λ exp((β + α)ts + η′x)
+
1− exp((β + α)ts)
(β + α) exp((β + α)ts)
+ ts, if
− log(u) ≥ λ exp(η
′x)
β + α
[ exp((β + α)ts)− 1] (12)
where u ∼ U(0, 1).
A3: multiple-dose approach assuming imperfect infusion adherence
In a multiple-dose setting, perfect adherence to the 8-weekly infusion schedule is not
always assured. If the “zero-protection” threshold ts is smaller than a dosing interval,
then modifications of the derivations covered in Section 2.2.2 are needed when the next
infusion occurs after ts has passed.
As stated in Section 2.2.1, in a single-dose setting, for t > ts, the cumulative hazard
function is equal to
H(t, x, z(t)) =
λ exp(η′x)
β
[exp(βt)− 1] + λ exp(η′x)(t− ts) exp(βts).
And, an event time can be generated as
T =
− log(u)
λ exp(βts + η′x)
+
1− exp(βts)
β exp(βts)
+ ts, if
− log(u) ≥ λ exp(η
′x)
β
[exp(βts)− 1], (13)
where u ∼ U(0, 1).
As stated in Section 2.2.2, in a multiple-dose setting, for tk ≤ t < tk+1, k = 1....,m−
1, the cumulative hazard function is equal to
H(t, x, z(t)) =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) + exp(βt− βtk)− k
]
.
And, the event time can be generated as
T =
1
β
log
(
exp(βtk)
(
β(− log(u))
λ exp(η′x)
−
k∑
i=2
exp(β(ti − ti−1)) + k
))
, if
a ≤ − log(u) < b, (14)
where,
a =
λ
β
exp(η′x)
(
k∑
i=2
exp(β(ti − ti−1))− (k − 1)
)
,
b =
λ
β
exp(η′x)
(
k∑
i=2
exp(β(ti − ti−1)) + exp(βtk+1 − βtk)− k
)
,
and, u ∼ U(0, 1).
Now consider tk + ts ≤ t < tk+1 in a multiple-dose setting, where all infusions up
till the kth perfectly adhere to the 8-weekly schedule. The cumulative hazard function
is equal to
H(t, x, z(t)) =
∫ t
0
exp(βz(u) + η′x)du
= λ exp(η′x)
∫ t
0
exp(βz(u))du
= λ exp(η′x)
[∫ tk
0
exp(βz(u))du+
∫ tk+ts
tk
exp(β(u− tk)du+
∫ t
tk+ts
exp(β(ts))du
]
=
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) + exp(β(ts)) + β(t− ts − tk) exp(β(ts))− k
]
.
And, the inverse cumulative function is
H−1(u) =
1
β exp(βts)
(
βu
λ exp(η′x)
−
k∑
i=2
exp(β(ti − ti−1))− exp(βts) + k
)
+ ts + tk.
Therefore, an event time can be generated as
T =
1
β exp(βts)
(
β(− log(u))
λ exp(η′x)
−
k∑
i=2
exp(β(ti − ti−1))− exp(βts) + k
)
+ ts + tk, if
a ≤ − log(u) < b, (15)
where,
a =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) + exp(βts)− k
]
,
b =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) + exp(βtk+1 − βtk)− k
]
,
and, u ∼ U(0, 1).
If more infusions continue to be given after a violation of the infusion schedule, and
tk+n ≤ t < tk+n + ts and tk ≤ tk + ts < tk+1, then the cumulative hazard function is
equal to
H(t, x, z(t)) =
∫ t
0
exp(βz(u) + η′x)du
=λ exp(η′x)
∫ t
0
exp(βz(u))du
=λ exp(η′x)
(∫ tk
0
exp(βz(u)du+
∫ tk+ts
tk
exp(β(u− tk)du
+
∫ tk+1
tk+ts
exp(β(ts))du+
∫ t
tk+1
exp(βz(u))du
)
=
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) +
k+n∑
i=k+2
exp(β(ti − ti−1))
+ exp(βt− βtk+n) + β(tk+1 − ts − tk) exp(βts) + exp(βts)− (k + n)
]
.
And, the inverse cumulative function is
H−1(u) =
1
β
log
(
exp(βtk+n)
(
β(u)
λ exp(η′x)
−
k∑
i=2
exp(β(ti−ti−1))−
k+n∑
i=k+2
exp(β(ti−ti−1))
− β(tk+1 − ts − tk) exp(βts)− exp(βts) + (k + n)
))
.
Therefore, an event time can be generated as
T =
1
β
log
(
exp(βtk+n)
(
β(− log(u))
λ exp(η′x)
−
k∑
i=2
exp(β(ti− ti−1))−
k+n∑
i=k+2
exp(β(ti− ti−1))
− β(tk+1 − ts − tk) exp(βts)− exp(βts) + (k + n)
))
, if a ≤ − log(u) < b, where
a =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) +
k+n∑
i=k+2
exp(β(ti − ti−1))
+ β(tk+1 − ts − tk) exp(βts) + exp(βts)− (k + n− 1)
]
,
b =
λ
β
exp(η′x)
[
k∑
i=2
exp(β(ti − ti−1)) +
k+n∑
i=k+2
exp(β(ti − ti−1))
+ exp(βtk+n+1 − βtk+n) + β(tk+1 − ts − tk) exp(βts) + exp(βts)− (k + n)
]
,
and u ∼ U(0, 1).
The strategies described above can be extrapolated to settings where multiple vio-
lations to the 8-weekly infusion schedule occur.
